IP Library Granted Patent US 6,974,839
Granted Patent B2
US 6,974,839 · App. 10/098,826 · Granted Dec 13, 2005

Method of delaying ejaculation

Assignee: DMI BioSciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,974,839
App. No.
10/098,826
Granted
Dec 13, 2005
Kind
B2
Abstract

The invention provides a method of delaying ejaculation. The method comprises administering an effective amount of a tramadol material to a human male prior to sexual intercourse. The method is particularly useful for treating premature ejaculation.

Claims (17)

1. A method of delaying ejaculation during sexual intercourse comprising administering orally to a human male who suffers from premature ejaculation prior to the sexual intercourse an effective amount of a compound selected from the group consisting of tramadol, a pharmaceutically-acceptable form of tramadol, tramadol-oxide, a pharmaceutically-acceptable form of tramadol N-oxide, O-desmethyl tramadol, a pharmaceutically-acceptable form of O-desmethyl tramadol and mixtures of the foregoing.

2. The method of claim 1 wherein the compound is tramadol or a pharmaceutically-acceptable salt thereof.

3. The method of claim 2 wherein the tramadol is (±) cis-tramadol or a pharmaceutically-acceptable salt thereof.

4. The method of claim 3 wherein a dose of from about 10 to about 50 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

5. The method of claim 4 wherein a dose of from about 15 to about 35 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

6. The method of claim 4 wherein a dose of about 25 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

7. The method of claim 3 wherein a (+)-enantiomer of the cis-tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

8. The method of claim 3 wherein a (−)-enantiomer of the cis-tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

9. The method of claim 3 wherein the tramadol material is (±) cis-tramadol hydrochloride.

10. The method of claim 9 wherein a dose of from about 10 to about 50 milligrams of the tramadol hydrochloride is administered to the male.

11. The method of claim 10 wherein a dose of from about 15 to about 35 milligrams of the tramadol hydrochloride is administered to the male.

12. The method of claim 10 wherein a dose of about 25 milligrams of the tramadol hydrochloride is administered to the male.

13. The method of any one of claims 1 – 12 or 14 – 17 wherein the compound is administered from about 30 minutes to about 60 minutes prior to sexual intercourse.

14. The method of claim 4 wherein a dose of from about 10 to about 35 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

15. The method of claim 4 wherein a dose of from about 25 to about 35 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

16. The method of claim 10 wherein a dose of from about 10 to about 35 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

17. The method of claim 10 wherein a dose of from about 25 to about 35 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

Assignments (5)
MERGER Recorded Aug 20, 2015
From: VYRIX PHARMACEUTICALS, INC.
To: ROSEWIND CORPORATION
Reel/Frame 036379/0212 →
CERTIFICATES OF CONVERSION AND INCORPORATION Recorded Aug 20, 2015
From: ROSEWIND CORPORATION
To: AYTU BIOSCIENCE, INC.
Reel/Frame 036399/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2014
From: AMPIO PHARMACEUTICALS, INC.
To: VYRIX PHARMACEUTICALS, INC.
Reel/Frame 031873/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2013
From: DMI BIOSCIENCES, INC.
To: AMPIO PHARMACEUTICALS, INC.
Reel/Frame 031141/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2002
From: BAR-OR, DAVID
To: DMI BIOSCIENCES, INC.
Reel/Frame 012717/0321 →
Continuity (2)
Provisional Application 6027680600 · Mar 16, 2001
Related Publication 20020132857A1 · Sep 19, 2002